Jonan-ku, Fukuoka-shi, Japan
A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC in Adults With Ocular Myasthenia Gravis
Phase
3Span
172 weeksSponsor
argenxFukuoka
Recruiting
Focused Research On Neurofeedback Therapy In Eradicating Depression (FRONTIER)
Phase
1/2Span
71 weeksSponsor
UNB Sumiyoshi Jinja Mae ClinicFukuoka
Recruiting
Investigational Study of SWM-831 to Treat Moderate and Severely Calcified Femoropopliteal Arteries
Up to 60 subjects at up to 10 sites in Japan will be enrolled in the femoropopliteal clinical study with moderate and severely calcified femoropopliteal artery disease presenting with Rutherford Category 2 - 5 of the target limb. Two additional cohorts [Iliac and BTK (Below-the-Knee)] will enroll a minimum of 10 and a maximum of 15 subjects each with moderate and severely calcified iliac disease with a Rutherford Category (RC) 2 - 5 and a minimum of 10 and a maximum of 15 subjects with moderate and severely calcified BTK lesions with a Rutherford Category (RC) 2 - 5 will be enrolled and followed through 12 months. The estimated study duration for these cohorts is approximately 24 months. Study subjects will be followed through discharge, 30 days, 6, and 12 months.
Phase
N/ASpan
156 weeksSponsor
Shockwave Medical, Inc.Fukuoka
Recruiting
Study of Obeldesivir to Treat Children With Respiratory Syncytial Virus (RSV) Infection
Pediatric participants will be enrolled as follows: - Cohort 1: Infants and children from 4 weeks postnatal age, weighing ≥ 1.5 kg to < 40 kg - Cohort 2: Neonates, either born at term or preterm, weighing ≥ 1.5 kg to < 6 kg
Phase
2Span
61 weeksSponsor
Gilead SciencesFukuoka
Recruiting
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
Phase
3Span
374 weeksSponsor
Merck Sharp & Dohme LLCFukuoka
Recruiting
A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations
This trial will evaluate the safety and efficacy of valemetostat tosylate (DS-3201b) in combination with fixed-dose pembrolizumab versus pembrolizumab alone in participants with advanced or metastatic NSCLC without actionable genomic alterations, whose tumor has PD-L1 TPS ≥50%, and who have not received prior systemic therapy for advanced or metastatic NSCLC. The trial will be in 2 phases, dose escalation and dose expansion phases.
Phase
1/2Span
287 weeksSponsor
Daiichi SankyoFukuoka
Recruiting
A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (PAH) (MK-7962-024)
Phase
2Span
87 weeksSponsor
Merck Sharp & Dohme LLCFukuoka
Recruiting
A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus
Phase
3Span
147 weeksSponsor
UCB Biopharma SRLFukuoka
Recruiting
Study of Oral ABBV-932 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Bipolar I or II Disorder
Phase
2Span
81 weeksSponsor
AbbVieFukuoka
Recruiting
Software as a Medical Device for the Treatment of Patients With PTSD
Phase
2/3Span
179 weeksSponsor
Otsuka Medical Devices Co., Ltd. JapanFukuoka
Recruiting